Skip to main content
. 2020 Jan 27;64(2):e01711-19. doi: 10.1128/AAC.01711-19

FIG 3.

FIG 3

Aminoglycoside susceptibility of isolates with the NDM (New Delhi metallo-β-lactamase) resistance mechanism (n = 42), determined using CLSI, EUCAST, and FDA breakpoints. S, susceptible; I, CLSI intermediate and EUCAST susceptible increased exposure categories; R, resistant; PLZ, plazomicin; AMK, amikacin; GEN, gentamicin; TOB, tobramycin.